Investigating the influence of ribavirin on human respiratory syncytial virus rna synthesis by using a high-resolution transcriptome sequencing approach

Journal of Virology

Volumn 90, Issue 10, 2016, Pages 4876-4888

  Aljabr, Waleed ^a,b   Touzelet, Olivier ^a   Pollakis, Georgios ^a,b   Wu, Weining ^a   Munday, Diane C ^a   Hughes, Margaret ^a   Hertz Fowler, Christiane ^a   Kenny, John ^a   Fearns, Rachel ^c   Barr, John N ^d   Matthews, David A ^e   Hiscox, Julian A ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NIHR Health Protections Research Unit in Emerging and Zoonotic Infections   (United Kingdom)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; RNA POLYMERASE; TRANSCRIPTOME; VIRUS RNA; ANTIVIRUS AGENT; BETA INTERFERON;

ARTICLE; BIOACCUMULATION; CELL POPULATION; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUTATION RATE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHASE TRANSITION; PRIORITY JOURNAL; REPLICON; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RNA ANALYSIS; RNA SEQUENCE; RNA SYNTHESIS; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; PROCEDURES; VIRAL PLAQUE ASSAY; VIROLOGY; VIRUS ATTACHMENT; VIRUS ENTRY;

ANTIVIRAL AGENTS; GENOME, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTERFERON-BETA; MUTATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RIBAVIRIN; RNA, VIRAL; TRANSCRIPTOME; VIRAL PLAQUE ASSAY; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84977098569     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02349-15     Document Type: Article

References (52)

1. Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82:2040-2055. http://dx.doi.org/10 .1128/JVI.01625-07.
2. Committee on Infectious Diseases. 2009. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124:1694-1701. http://dx.doi.org/10.1542/peds.2009-2345.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. NEngl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
4. Van Drunen Littel-Van Den Hurk S, Watkiss ER. 2012. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2:300-305. http://dx.doi.org /10.1016/j.coviro.2012.01.008.
5. MacLellan K, Loney C, Yeo R, Bhella D. 2007. The 24-angstrom structure of respiratory syncytial virus nucleocapsid protein-RNA decameric rings. J Virol 81:9519-9524. http://dx.doi.org/10.1128/JVI.00526-07.
6. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
7. Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus:virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372:3-38. http://dx.doi.org/10.1007/978-3-642-38919-1_1.
8. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagne N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eleouet JF, Rey FA. 2009. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326:1279-1283. http://dx.doi.org/10.1126/science.1177634.
9. Mazumder B, Barik S. 1994. Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: transdominant negative phenotype of phosphorylation- defective P mutants. Virology 205:104-111. http://dx.doi .org/10.1006/viro.1994.1624.
10. Noton SL, Deflube LR, Tremaglio CZ, Fearns R. 2012. The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog 8:e1002980. http://dx.doi.org/10.1371/journal .ppat.1002980.
11. Fearns R, Collins PL. 1999. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol 73:5852-5864.
12. Collins PL, Hill MG, Cristina J, Grosfeld H. 1996. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negativestrand RNA virus. Proc Natl Acad Sci U S A 93:81-85. http://dx.doi.org /10.1073/pnas.93.1.81.
13. Galloux M, Tarus B, Blazevic I, Fix J, Duquerroy S, Eleouet JF. 2012. Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein. J Virol 86:8375-8387. http://dx .doi.org/10.1128/JVI.00058-12.
14. Noton SL, Fearns R. 2015. Initiation and regulation of paramyxovirus transcription and replication. Virology 479-480:545-554. http://dx.doi .org/10.1016/j.virol.2015.01.014.
15. Collins PL, Dickens LE, Buckler-White A, Olmsted RA, Spriggs MK, Camargo E, Coelingh KV. 1986. Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci U S A 83:4594-4598. http://dx.doi.org/10.1073/pnas.83.13.4594.
16. Kuo L, Grosfeld H, Cristina J, Hill MG, Collins PL. 1996. Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. J Virol 70:6892-6901.
17. Dickens LE, Collins PL, Wertz GW. 1984. Transcriptional mapping of human respiratory syncytial virus. J Virol 52:364-369.
18. Tremaglio CZ, Noton SL, Deflube LR, Fearns R. 2013. Respiratory syncytial virus polymerase can initiate transcription from position 3 of the leader promoter. J Virol 87:3196-3207. http://dx.doi.org/10.1128/JVI .02862-12.
19. Barik S. 1992. Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor(s). J Virol 66:6813-6818.
20. Chu HY, Englund JA. 2013. Respiratory syncytial virus disease: prevention and treatment. Curr Top Microbiol Immunol 372:235-258. http://dx .doi.org/10.1007/978-3-642-38919-1_12.
21. Waghmare A, Campbell AP, Xie H, Seo S, Kuypers J, Leisenring W, Jerome KR, Englund JA, Boeckh M. 2013. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 57:1731-1741. http://dx.doi.org/10.1093/cid/cit639.
22. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, RaDenne S, Coilly A, Garrigue V, D'Alteroche L, Buchler M, Couzi L, Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM, Abravanel F, Pol S, Rostaing L, Mallet V. 2014. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 370:1111-1120. http://dx.doi.org/10.1056/NEJMoa1215246.
23. Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, Fuller C, Daumer M, Teuber G, Wedemeyer H, Berg T, Lengauer T, Zeuzem S, Herrmann E, Sarrazin C. 2013. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 87:6172- 6181. http://dx.doi.org /10.1128/JVI.02778-12.
24. Soares-Weiser K, Thomas S, Thomson G, Garner P. 2010. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect Dis 10:207. http://dx.doi.org/10.1186/1471-2334-10-207.
25. Willis RC, Carson DA, Seegmiller JE. 1978. ADenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A 75:3042-3044. http://dx.doi.org/10.1073/pnas.75.7 .3042.
26. Zimmerman TP, Deeprose RD. 1978. Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5=-triphosphates in human blood and L5178Y cells. Biochem Pharmacol 27:709-716. http://dx.doi.org/10.1016/0006-2952(78)90508-7.
27. Dixit NM, Perelson AS. 2006. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 63:832-842. http://dx.doi.org/10.1007/s00018-005-5455-y.
28. Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16:37-48. http://dx.doi.org/10.1002/rmv .483.
29. Paeshuyse J, Dallmeier K, Neyts J. 2011. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 1:590-598. http://dx.doi.org/10.1016/j.coviro .2011.10.030.
30. Cameron CE, Castro C. 2001. The mechanism of action of ribavirin:lethal mutagenesis of RNA virus genomes mediated by the viral RNAdepenDent RNA polymerase. Curr Opin Infect Dis 14:757-764.
31. Vignuzzi M, Stone JK, Andino R. 2005. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res 107:173-181. http://dx.doi.org/10.1016/j.virusres.2004 .11.007.
32. Vo NV, Young KC, Lai MM. 2003. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42:10462-10471. http://dx.doi.org/10.1021/bi0344681.
33. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe:direct molecular test by using ribavirin. Proc Natl Acad SciUS A 98:6895-6900. http://dx.doi.org/10.1073/pnas.111085598.
34. Smee DF, Matthews TR. 1986. Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells. Antimicrob Agents Chemother 30:117-121. http://dx.doi.org/10.1128/AAC.30.1.117.
35. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947. http://dx.doi.org/10.1128/JVI.79.3.1943-1947.2005.
36. Topfer A, Zagordi O, Prabhakaran S, Roth V, Halperin E, Beerenwinkel N. 2013. Probabilistic inference of viral quasispecies subject to recombination. J Comput Biol 20:113-123. http://dx.doi.org/10.1089/cmb.2012 .0232.
37. Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, Garcia-Dorival I, Bore JA, Koundouno R, Abdellati S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Badusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B, Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour S, Ehichioya D, Ellerbrok H, Fenandez-Garcia MD, Fizet A, Fleischmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U, Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J, Molkenthin P, Muñoz-Fontela C, Muth D, Newman EN, Ngabo D, Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E, Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G, Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Vermoesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR, Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CE, Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK, Koivogui L, Magassouba N, Avšič-Županc T, Nitsche A, Strasser M, Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A, Wölfel R, Formenty P, Günther S. 2015. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature 524:97-101. http://dx.doi.org/10.1038/nature14594.
38. Hruska JF, Bernstein JM, Douglas RG, Jr, Hall CB. 1980. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 17:770-775. http://dx.doi.org/10.1128/AAC.17.5.770.
39. Dowall SD, Matthews DA, Garcia-Dorival I, Taylor I, Kenny J, Hertz-Fowler C, Hall N, Corbin-Lickfett K, Empig C, Schlunegger K, Barr JN, Carroll MW, Hewson R, Hiscox JA. 2014. Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome Biol 15:540. http://dx.doi.org/10.1186/s13059-014-0540-x.
40. Cartee TL, Megaw AG, Oomens AGP, Wertz GW. 2003. IDentification of a single amino acid change in the human respiratory syncytial virus L protein that affects transcriptional termination. J Virol 77:7352-7360. http://dx.doi.org/10.1128/JVI.77.13.7352-7360.2003.
41. Wynne JW, Shiell BJ, Marsh GA, Boyd V, Harper JA, Heesom K, Monaghan P, Zhou P, Payne J, Klein R, Todd S, Mok L, Green D, Bingham J, Tachedjian M, Baker ML, Matthews D, Wang LF. 2014. Proteomics informed by transcriptomics reveals Hendra virus sensitizes bat cells to TRAIL mediated apoptosis. Genome Biol 15:532.
42. Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O, Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de Oliveira AP, Simabuco FM, Ventura AM, Hughes DJ, Barr JN, Fearns R, Digard P, Eleouet JF, Hiscox JA. 2015. Interactome analysis of the human respiratory syncytial virus RNA polymerase complex iDentifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis. J Virol 89:917-930. http://dx.doi.org/10.1128/JVI .01783-14.
43. Geller R, Andino R, Frydman J. 2013. Hsp90 inhibitors exhibit resistance- free antiviral activity against respiratory syncytial virus. PLoS One 8:e56762. http://dx.doi.org/10.1371/journal.pone.0056762.
44. Radhakrishnan A, Yeo D, Brown G, Myaing MZ, Iyer LR, Fleck R, Tan BH, Aitken J, Sanmun D, Tang K, Yarwood A, Brink J, Sugrue RJ. 2010. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol Cell Proteomics 9:1829-1848. http://dx.doi.org/10 .1074/mcp.M110.001651.
45. Connor JH, McKenzie MO, Parks GD, Lyles DS. 2007. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 362:109-119. http://dx.doi.org/10 .1016/j.virol.2006.12.026.
46. Anderson JP, Daifuku R, Loeb LA. 2004. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58:183-205. http://dx.doi .org/10.1146/annurev.micro.58.030603.123649.
47. Drake JW. 1993. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90:4171-4175. http://dx.doi.org/10.1073/pnas .90.9.4171.
48. Crotty S, Andino R. 2002. Implications of high RNA virus mutation rates:lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 4:1301-1307. http://dx.doi.org/10.1016/S1286-4579(02)00008-4.
49. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med (Berl) 80:86-95. http://dx.doi .org/10.1007/s00109-001-0308-0.
50. Samuel CE. 2011. ADenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 411:180-193. http://dx.doi.org/10 .1016/j.virol.2010.12.004.
51. Stark JM, Barmada MM, Winterberg AV, Majumber N, Gibbons WJ, Jr, Stark MA, Sartor MA, Medvedovic M, Kolls J, Bein K, Mailaparambil B, Krueger M, Heinzmann A, Leikauf GD, Prows DR. 2010. Genomewide association analysis of respiratory syncytial virus infection in mice. J Virol 84:2257-2269. http://dx.doi.org/10.1128/JVI.00584-09.
52. Martinez I, Melero JA. 2002. A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for aDenosine deaminases that act on RNA. J Gen Virol 83:1445-1455. http://dx.doi.org/10.1099/0022-1317-83-6-1445.